In a population with type 2 diabetes who are at high risk or have established CVD, participants with high levels of FGF-23 were associated with an increased risk of the composite of CV death/HHF and the individual endpoint HHF, whereas participants with high levels of hsCRP were associated with an increased risk of CV death and MACE, independent of clinical risk factors and traditional CV or renal biomarkers as summarized in the Central Illustration. This evidence concerns the gene FGF23 and type 2 diabetes mellitus.